Side-by-side · Research reference
HGH Fragment 176-191vsSNAP-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
01Mechanism of Action
Parameter
HGH Fragment 176-191
SNAP-8
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
SNARE complex (SNAP-25 competitive binding site)
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
N/A — topical cosmetic, no systemic endocrine axis
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
SNAP-8
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Frequency
Once daily (animal models)
—
Evidence basis
Animal studies only
RCT, in vitro skin penetration studies
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Typical concentration
—
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Treatment duration
—
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
—
Oil-in-water emulsion, serum, cream
Application site
—
Facial skin — glabellar lines, crow's feet, forehead
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
SNAP-8
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
04Side Effects & Safety
Parameter
HGH Fragment 176-191
SNAP-8
Human safety data
Not available — no published human trials
—
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
Cytotoxicity
—
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
—
Minimal; well-tolerated in clinical use
Peptide oxidation
—
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Hypersensitivity
—
Rare; no widespread allergic reactions reported
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
05Administration Protocol
Parameter
HGH Fragment 176-191
SNAP-8
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
—
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.